New Perspectives on Hypogonadism and Testosterone Replacement in Clinical Practice Join 4 experts as they review the e�ect of hypogonadism and the role of testosterone replacement therapy in improving patient outcomes.

Alvaro Morales, MD, FRCSC, FACSProfessor Emeritus, Department of Urology, School of Medicine, Queen's University, Kingston, Ontario, Canada

Geo�rey Hackett, MD, FRCPI, MRCGPProfessor of Men’s Health, Department of Diabetes, University of Bedfordshire; Consultant in Urology, Good Hope Hospital, Sutton Cold�eld, United Kingdom

Abraham Morgentaler, MD, FACSFounder and Director, Men's Health Boston; Associate Clinical Professor of Surgery (Urology), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States

Michael Zitzmann, MD, PhDProfessor of Medicine, Endocrinologist, Andrologist, Diabetologist; Sexual Medicine (FECSM); Clinical Andrology, Centre for Reproductive Medicine and Andrology, Münster, Germany

EXPERTS

To learn more about testosterone replacement, consult our online program at: www.medscape.org/collection/hypogonadism

New Perspectives on Hypogonadism and Testosterone Replacement in Clinical Practice

Target AudienceThis activity is intended for a non-US audience, speci�cally primary care physicians, urologists, diabetologists/endocrinologists, cardiologists, and other healthcare professionals who need to be aware of symptoms or manage patients with hypogonadism.

GoalsThe goals of this activity are to help participants identify patients with hypogonadism; provide an overview of the e�ect of the condition on quality of life and mortality; and review the role of testosterone replacement therapy in prostate, metabolic, and cardiovascular (CV) health.

Learning Objectives Upon completion of this activity, participants will be able to:

• Identify the clinical e�ect of testosterone de�ciency on men's health, quality of life, and mortality

• Examine the latest clinical data on the interrelationships between hypogonadism and metabolic and CV risk factors, as well as between hypogonadism and prostate health

• Explain how to identify men at risk, diagnose hypogonadism, and how to treat and monitor patients, taking into account the latest clinical data and guidelines

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

Commercial Support AcknowledgmentThis educational activity is supported by an independent educational grant from Bayer AG.

Accreditation Statement

To learn more about testosterone replacement, consult our online program at:

www.medscape.org/collection/hypogonadismTo learn more about testosterone replacement, consult our online program at: www.medscape.org/collection/hypogonadism